On August 3, Moderna, Inc. rose 5.11% in regular trading, trading at $57.70/share, with turnover of $73.86 million.

On the news front, UBS raised its price target on Moderna from $45 to $50 while maintaining a neutral rating, and Bank of America Global Research simultaneously raised its target from $38 to $40. The synchronized upgrades from two major institutions sent a positive signal, serving as a short-term catalyst.

Additionally, the company's fifth product, Mflusiva, is approaching a critical FDA PDUFA review date on August 5, fueling market expectations for approval. The company's seasonal flu vaccine candidate mRNA-1010 previously received unanimous support from the FDA's advisory committee with a 9-0 vote in favor, further reinforcing market confidence. Moderna reported Q2 EPS of -$1.97, narrower than the estimated loss of -$2.01, while revenue of $145 million beat the $102.9 million consensus estimate.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)